Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10814207 | 0.83 | MEN1 (0.40) | MEN1KMT2AHTR2C | |
| SCHEMBL619655 | 0.83 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL28780846 | 0.82 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL10064328 | 0.82 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3HTR2C | |
| Faxeladol SCHEMBL5686250 | 0.81 | SLC6A4 (0.50) | SLC6A4SLC6A2MEN1KMT2AHTR2C | |
| SCHEMBL5205169 | 0.81 | CYP11B2 (0.49) | MEN1KMT2A | |
| Faxeladol SCHEMBL149507 | 0.81 | SLC6A4 (0.50) | SLC6A4SLC6A2MEN1KMT2AHTR2C | |
| Faxeladol SCHEMBL149508 | 0.81 | SLC6A4 (0.50) | SLC6A4SLC6A2MEN1KMT2AHTR2C | |
| SCHEMBL4870165 | 0.81 | CYP11B2 (0.49) | MEN1KMT2A | |
| Faxeladol SCHEMBL616828 | 0.81 | SLC6A4 (0.50) | SLC6A4SLC6A2MEN1KMT2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101125137-A | Pharmaceutical salts | GRUENENTHAL GMBH (DE) | 2008-02-20 | — | — | CN | claimed |
| EP-1429754-B1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2008-01-16 | — | — | EP | claimed |
| EP-1337246-B1 | USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2006-03-22 | — | — | EP | claimed |
| EP-1353660-B1 | USE OF SUBSTITUTED 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE COMPOUNDS FOR TREATING URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2006-01-11 | — | — | EP | claimed |
| US-20050176790-A1 | Pharmaceutical salts | GRUNENTHAL GMBH (DE) | 2005-08-11 | — | — | US | claimed |
| US-20050137194-A1 | Combination of selected opioids with other active compounds for treatment of urinary incontinence | GRUENENTHAL GMBH (DE) | 2005-06-23 | — | — | US | claimed |
| CN-1561203-A | Pharmaceutically acceptable salts | GRUENENTHAL GMBH (DE) | 2005-01-05 | — | — | CN | claimed |
| US-20040242617-A1 | active at very low doses, therefore low side effect profile | GRUENENTHAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| CN-1122018-C | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | GRUENENTHAL GMBH (DE) | 2003-09-24 | — | — | CN | claimed |
| US-RE37355-E1 | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | GRUENENTHAL GMBH (DE) | 2001-09-04 | — | — | US | claimed |
| EP-0753506-B1 | 6-Dimethylaminomethyl-1-phenyl-cyclo-hexane compounds as pharmaceutical agents | GRUENENTHAL GMBH (DE) | 1999-08-18 | — | — | EP | claimed |
| US-5733936-A | ANALGESICS | GRUENENTHAL GMBH (DE) | 1998-03-31 | — | — | US | claimed |
| CN-1146987-A | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | GRUENENTHAL GMBH (DE) | 1997-04-09 | — | — | CN | claimed |
| JP-9031033-A | — | — | None | — | — | JP | disclosed |
| US-10160719-B2 | Pharmaceutical salts | GRUNENTHAL GMBH (DE) | 2018-12-25 | — | — | US | disclosed |
| US-20170137370-A1 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2017-05-18 | — | — | US | disclosed |
| CN-1146987-A | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | GRUENENTHAL GMBH (DE) | 1997-04-09 | — | — | CN | disclosed |
| JP-H0931033-A | 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE COMPOUND AS MEDICINALLY EFFECGIVE SUBSTANCE | GRUENENTHAL GMBH | 1997-02-04 | — | — | JP | disclosed |
| EP-0753506-A1 | 6-Dimethylaminomethyl-1-phenyl-cyclo-hexane compounds as pharmaceutical agents | Grünenthal GmbH (DE) | 1997-01-15 | — | — | EP | disclosed |
| EP-0753506-A1 | 6-Dimethylaminomethyl-1-phenyl-cyclo-hexane compounds as pharmaceutical agents | Grünenthal GmbH (DE) | 1997-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242617-A1 | active at very low doses, therefore low side effect profile | OPRM1, OPRK1, OPRD1 | SLC6A4 406/4885SLC6A2 252/4885SLC6A3 138/4885 |
| US-20050176790-A1 | Pharmaceutical salts | SLC5A1, SLC5A2, SLC35A1 | SLC6A4 106/4885SLC6A2 217/4885SLC6A3 182/4885 |
| US-20050137194-A1 | Combination of selected opioids with other active compounds for treatment of urinary incontinence | OPRM1, OPRK1, OPRL1 | SLC6A4 131/4885SLC6A2 52/4885SLC6A3 38/4885 |
| US-10160719-B2 | Pharmaceutical salts | SLC5A1, SLC5A2, SLC35A1 | SLC6A4 83/4885SLC6A2 164/4885SLC6A3 133/4885 |
| US-20170137370-A1 | PHARMACEUTICAL SALTS | SLC5A1, SLC5A2, SLC35A1 | SLC6A4 83/4885SLC6A2 164/4885SLC6A3 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.